Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice.
Or get in touch at support@businessoffashion.com
if you experience difficulties.
